Nantkwest Inc (NDAQ:NK) had its price objective hoisted by stock analysts at FBR & Co from $9.00 to $22.00 in a research report issued on Friday. The brokerage currently has an “outperform” rating on the stock.
Nantkwest (NDAQ:NK) opened at 3.55 on Friday. Nantkwest has a one year low of $3.41 and a one year high of $10.26. The stock’s 50 day moving average price is $4.75 and its 200 day moving average price is $6.39. The stock’s market cap is $292.43 million.
Your IP Address:
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
Receive News & Ratings for Nantkwest Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest Inc and related companies with MarketBeat.com's FREE daily email newsletter.